Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach

Table 3 Difference in methylated genes between cancer (PCa) samples and healthy (P) samples adjacent to the tumour

Gene	Training set			Validation set			AUC Validation set (95 % CI)
	Median value (range)		P value*	Median value (range)		P value*
	PCa	P	P value*	PCa	P	P value*
GSTP1	69.70 (0.00–100.00)	0.00 (0.00–18.20)	<0.0001	35.50 (0.00–100.00)	2.81 (0.00–30.18)	<0.0001	0.89 (0.82–0.97)
RASSF1	49.25 (11.10–100.00)	5.00 (0.00–45.60)	<0.0001	46.69 (9.88–79.98)	9.63 (0.00–74.81)	<0.0001	0.92 (0.85–0.98)
CCND2	35.10 (4.40–94.60)	5.75 (0.00–27.10)	<0.0001	33.29 (7.26–100.00)	5.41 (0.00–38.45)	<0.0001	0.92 (0.86–0.98)
SCGB3A1	65.90 (12.40–100.00)	9.45 (0.00–28.80)	<0.0001	56.47 (0.00–100.00)	10.35 (0.00–35.04)	<0.0001	0.95 (0.90–1.00)
RARB	29.95 (4.60–71.50)	4.65 (0.00–16.10)	<0.0001	35.89 (2.29–100.00)	4.55 (0.00–18.71)	<0.0001	0.94 (0.88–0.99)
ID4	22.65 (4.30–100.00)	5.15 (0.00–11.90)	<0.0001	14.41 (0.00–45.32)	5.08 (0.00–16.08)	<0.0001	0.86 (0.78–0.94)
CACNA1A	12.95 (0.00–100.00)	0.00 (0.00–2.13)	0.0001	6.32 (0.00–68.89)	0.00 (0.00–14.94)	0.0001	0.74 (0.64–0.84)
SFRP5	7.50 (0.00–29.30)	0.00 (0.00–0.00)	<0.0001	8.35 (0.00–39.01)	0.00 (0.00–10.79)	<0.0001	0.82 (0.73–0.91)
APC	32.55 (0.00–71.00)	4.88 (0.00–59.10)	0.0001	36.77 (0.00–91.80)	5.89 (0.00–38.90)	<0.0001	0.84 (0.75–0.93)
CD44	5.60 (0.00–57.40)	0.00 (0.00–10.30)	0.0009	5.92 (0.00–59.33)	4.08 (0.00–29.70)	0.1391	–
CDH13	0.00 (0.00–39.00)	0.00 (0.00–14.40)	0.0087	9.43 (0.00–41.21)	5.99 (0.00–27.62)	0.0557	–
RUNX3	3.75 (0.00–44.10)	0.00 (0.00–29.60)	0.0088	9.71 (0.00–47.22)	8.38 (0.00–44.90)	0.3351	–

AUC area under ROC curve
* Wilcoxon test: prostate cancer samples (PCa) vs. healthy adjacent prostate samples (P)

ISSN: 1479-5876